Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Heart Failure 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

pembrolizumab 33Carboplatin 18Cisplatin 15Nivolumab 14Pemetrexed 12Paclitaxel 12Ipilimumab 11atezolizumab 10Gemcitabine 10venetoclax 9Radiotherapy 9Docetaxel 9durvalumab 8Cyclophosphamide 8fludarabine 7Specimen Handling 7Biopsy 7Bevacizumab 7tislelizumab 6enzalutamide 6Trastuzumab 6Practice Guidelines as Topic 6Cetuximab 6tazemetostat 5fludarabine phosphate 5Surveys and Questionnaires 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × empagliflozin × 90 days × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡